Search results for: methotrexate

FDA Approves the Biosimilar Hadlima (Adalimumab-bwwd)

Michele B. Kaufman, PharmD, BCGP | September 16, 2019

Hadlima (adalimumab-bwwd), which is biosimilar to adalimumab, is now FDA approved to treat multiple autoimmune diseases…

Catch Your Breath: Insights into ILD in RA Patients

Jason Liebowitz, MD, FACR | September 12, 2019

Detecting interstitial lung disease in RA patients can be challenging. But evaluating risk factors and the use of imaging can help clinicians identify and manage this condition in patients…

Stay the Course: How to Maintain Remission in Vasculitis

Jason Liebowitz, MD, FACR | September 9, 2019

MADRID—During the 2019 European Congress of Rheumatology (EULAR), held June 12–15, speakers addressed the complexity of vasculitis in a Challenges in Clinical Practice session titled, How to Maintain Remission in Vasculitis. Although vasculitis appears in many varieties, one commonality exists among these related yet distinct conditions: When there is vital organ or systemic involvement, disease…

Updates to Axial Spondyloarthritis Guideline

Carina Stanton | September 5, 2019

A 2019 update of the ACR’s previous clinical practice guideline on axial spondyloarthritis is now available online. Lead investigator Michael Ward, MD, shares advice for implementing the guideline updates, including those related to sequencing and tapering biologics, and knowing when to obtain images.

FDA Approves Upadacitinib for RA

Michele B. Kaufman, PharmD, BCGP | September 2, 2019

Results from multiple phase 3 clinical trails have led to the FDA approval of upadacitinib to treat patients with moderate to severe active RA…

Filgotinib Promising for RA

Michele B. Kaufman, PharmD, BCGP | August 26, 2019

Research shows filgotinib may be safe and effective for treating rheumatoid arthritis. The drug’s manufacturer is expected to be submit a new drug application for filgotinib to the FDA in 2019…

Otilimab Begins Phase 3 Clinical Studies for RA

Michele B. Kaufman, PharmD, BCGP | August 19, 2019

In a four-part clinical trial program, researchers are assessing the safety and efficacy of otilimab with placebo in RA patients, along side conventional treatments, such as tofacitinib, and DMARDs…

Study Probes Whether Belimumab Can Lower Vasculitis Relapse Rate

Catherine Kolonko | August 16, 2019

In an international clinical trial, adding the drug belimumab to standard maintenance therapy for patients in remission with vasculitis did not lower the relapse rate. The double-blind, placebo-controlled study evaluated the safety and efficacy of belimumab as adjunctive therapy to maintain remission in anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). Results of the multi-center, industry-sponsored…

Study Probes New Gene Therapy for Severe, Localized Scleroderma (Morphea)

Ruth Jessen Hickman, MD | August 16, 2019

In September 2018, the U.S. Food & Drug Administration (FDA) granted fast-track status to FCX‑013, a gene therapy product developed to treat moderate to severe localized scleroderma (morphea). Previously, the treatment received an orphan drug designation for localized scleroderma, as well as a rare pediatric disease designation. Phase 1 and 2 studies will assess safety…

This chest CT shows new left upper lobe groundglass opacity.

Case Report: Could Myocarditis + Shortness of Breath = EGPA?

Ambreesh Chawla, MD, Ashwini Komarla, MD, & Sujatha Vuyyuru, MD | August 16, 2019

Eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome or allergic granulomatosis and angiitis, is a rare small- and medium-vessel vasculitis. This disease was first described by American pathologists Jacob Churg and Lotte Strauss in 1951.1 Although the vasculitis is often not apparent in the initial phases of the disease, EGPA can affect any…